The biotech industry has tried — and repeatedly failed — to develop new and effective painkillers without the addictive potential of opioids. But that could begin to change soon.

Sales easily beat expectations at nearly $2.59 billion. Vertex also earned an adjusted $4.38 per share, up 7% and ahead of forecasts for $4.08 a share.

VX-264 and zimislecel came from Vertex’s 2019 acquisition of privately held Semma Therapeutics. The $950 million deal established Vertex’s presence in type 1 diabetes therapy R&D.

It may be the end of the road for VX-264, but Vertex still has another islet cell treatment in development in the form of zimislecel. This allogeneic human stem cell-derived islet cell therapy is ...

Vertex also recently began a phase 2 trial in another form of neuropathic pain, known as painful lumbosacral radiculopathy (LSR), which has no FDA-approved drugs. According to Arbuckle, “40% of ...

BOSTON-- (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex doesn't pay a dividend at present, which is unusual among the "Big Pharma" sector. However, its stock is up nearly 60% on a five-year basis, and remarkably, up >150% since October 2021.

Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S ...

Vertex Pharmaceuticals is not making its drug, Trikafta, available in poorer countries, where thousands of diagnosed patients stand to benefit. Shwetha Sree, left, with her 5-year-old son Vihaan ...